Association of baseline vitamin D levels with clinical parameters and treatment outcomes in chronic hepatitis B
Association of baseline vitamin D levels with clinical parameters and treatment outcomes in chronic hepatitis B
复制标题
DOI：
10.1016/j.jhep.2015.06.025
复制
发表时间：
2015-11-01
影响因子：
25.7
通讯作者：
Marcellin, Patrick
中科院分区：
文献类型：
--
作者：
Chan, Henry Lik-Yuen;Elkhashab, Magdy;Marcellin, Patrick
背景与目的：维生素D水平与慢性乙型肝炎（CHB）感染和治疗结果之间的关系尚不清楚。在一项全球临床试验中，我们测量了治疗前血清维生素D（25-羟基维生素D-3； 25[OH]D-3）水平，并确定其与无晚期肝病的活动性慢性乙型肝炎患者的临床参数和治疗结果的关系。方法：患者被随机分配到48周富马酸替诺福韦二氧吡酯（TDF）加聚乙二醇干扰素α -2a (PegIFN)， TDF加聚乙二醇干扰素16周，然后是TDF 32周，PegIFN 48周，或TDF 120周。进行单因素和多因素分析以确定维生素D、基线因素和第48周临床结果之间的关系。结果：737例患者中，35%的患者>= 20
Background & Aims: The relationship between vitamin D levels and chronic hepatitis B (CHB) infection and treatment outcomes are poorly elucidated. We measured pre-treatment serum vitamin D (25-hydroxyvitamin D-3; 25[OH]D-3) levels and determined their association with clinical parameters and treatment outcomes in active CHB patients without advanced liver disease enrolled in a global clinical trial.Methods: Patients were randomly assigned to either 48 weeks of tenofovir disoproxil fumarate (TDF) plus peginterferon alfa-2a (PegIFN), TDF plus PegIFN for 16 weeks followed by TDF for 32 weeks, PegIFN for 48 weeks, or TDF for 120 weeks. Univariate and multivariate analyses were conducted to determine associations between vitamin D, baseline factors, and week 48 clinical outcome.Results: Of 737 patients, 35% had insufficient (>= 20 but